CVR number 16271187K
Industry 21.2000 Manufacture of pharmaceutical preparations

BAVARIAN NORDIC A/S - Group

 

Quicksearch
from your own companies
Analyst: XBRLDenmarkIFRS
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  29.3% 0.5% 1.2% 0.9% 0.5%  
Credit score (0-100)  2 99 80 89 98  
Credit rating  C AAA A A AA  
Credit limit (mDKK)  0.0 527.5 155.0 552.1 1,238.4  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 1,852 1,898 3,151 7,062  
Gross profit  0.0 657 570 1,701 4,603  
EBITDA  0.0 380 -314 -70.8 1,503  
EBIT  0.0 380 -314 -70.8 1,503  
Pre-tax profit (PTP)  0.0 282.0 -454.4 -331.6 1,482.9  
Net earnings  0.0 277.5 -464.8 -347.4 1,475.2  
Pre-tax profit without non-rec. items  0.0 282 -454 -332 1,483  
 
See the entire income statement

Balance sheet (mDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Tangible assets total  0.0 1,011 1,413 1,684 2,328  
Shareholders equity total  0.0 4,894 7,375 7,150 10,340  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 8,759 12,089 12,391 14,353  
Net Debt  0.0 -1,670 -3,717 -2,845 -1,867  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 1,852 1,898 3,151 7,062  
Net sales growth  -100.0% 0.0% 2.5% 66.0% 124.1%  
Gross profit  0.0 657 570 1,701 4,603  
Gross profit growth  -100.0% 0.0% -13.2% 198.3% 170.6%  
Employees  465 0 0 874 1,255  
Employee growth %  0.0% -100.0% 0.0% 0.0% 43.6%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 8,759 12,089 12,391 14,353  
Balance sheet change%  -100.0% 0.0% 38.0% 2.5% 15.8%  
Added value  0.0 379.6 -313.5 -70.8 1,502.5  
Added value %  0.0% 20.5% -16.5% -2.2% 21.3%  
Investments  -551 6,302 915 410 1,183  
Net sales trend  -2.0 0.0 1.0 2.0 3.0  
EBIT trend  0.0 1.0 -1.0 -2.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 20.5% -16.5% -2.2% 21.3%  
EBIT %  0.0% 20.5% -16.5% -2.2% 21.3%  
EBIT to gross profit (%)  0.0% 57.8% -55.0% -4.2% 32.6%  
Net Earnings %  0.0% 15.0% -24.5% -11.0% 20.9%  
Profit before depreciation and extraordinary items %  0.0% 15.0% -24.5% -11.0% 20.9%  
Pre tax profit less extraordinaries %  0.0% 15.2% -23.9% -10.5% 21.0%  
ROA %  0.0% 5.5% -2.5% 0.1% 12.1%  
ROI %  0.0% 6.1% -2.9% 0.1% 14.9%  
ROE %  0.0% 5.7% -7.6% -4.8% 16.9%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 56.4% 61.1% 57.7% 72.0%  
Relative indebtedness %  0.0% 208.6% 248.4% 166.3% 56.8%  
Relative net indebtedness %  0.0% 118.5% 52.6% 76.0% 30.4%  
Net int. bear. debt to EBITDA, %  0.0% -439.8% 1,185.3% 4,019.4% -124.3%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 2.1 2.3 1.6 1.3  
Current Ratio  0.0 2.5 2.5 2.0 1.9  
Cash and cash equivalent  0.0 1,669.6 3,716.6 2,845.2 1,867.5  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 27.4 73.4 60.6 91.9  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 128.5% 250.5% 142.3% 76.5%  
Net working capital  0.0 44.6 -279.7 -72.5 2,224.9  
Net working capital %  0.0% 2.4% -14.7% -2.3% 31.5%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 4 6  
Added value / employee  0 0 0 -0 1  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -0 1  
EBIT / employee  0 0 0 -0 1  
Net earnings / employee  0 0 0 -0 1